De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort study

  • 0Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Summary

No abstract available on PubMed